GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro
Cited 8 time in 
Metadata Downloads
Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | K S Hong | - |
| dc.contributor.author | J H Ahn | - |
| dc.contributor.author | J G Jang | - |
| dc.contributor.author | J H Lee | - |
| dc.contributor.author | H N Kim | - |
| dc.contributor.author | D Kim | - |
| dc.contributor.author | Wonhwa Lee | - |
| dc.date.accessioned | 2022-04-29T05:15:41Z | - |
| dc.date.available | 2022-04-29T05:15:41Z | - |
| dc.date.issued | 2020 | - |
| dc.identifier.issn | 2095-9907 | - |
| dc.identifier.uri | https://oak.kribb.re.kr/handle/201005/25829 | - |
| dc.publisher | Springer-Nature Pub Group | - |
| dc.title | GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro | - |
| dc.title.alternative | GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro | - |
| dc.type | Article | - |
| dc.citation.title | Signal Transduction and Targeted Therapy | - |
| dc.citation.number | 0 | - |
| dc.citation.endPage | 267 | - |
| dc.citation.startPage | 267 | - |
| dc.citation.volume | 5 | - |
| dc.contributor.affiliatedAuthor | Wonhwa Lee | - |
| dc.contributor.alternativeName | 홍경수 | - |
| dc.contributor.alternativeName | 안준홍 | - |
| dc.contributor.alternativeName | 장종걸 | - |
| dc.contributor.alternativeName | 이종호 | - |
| dc.contributor.alternativeName | 김홍남 | - |
| dc.contributor.alternativeName | 김동하 | - |
| dc.contributor.alternativeName | 이원화 | - |
| dc.identifier.bibliographicCitation | Signal Transduction and Targeted Therapy, vol. 5, pp. 267-267 | - |
| dc.identifier.doi | 10.1038/s41392-020-00391-5 | - |
| dc.description.journalClass | Y | - |
- Appears in Collections:
- 1. Journal Articles > Journal Articles
- Files in This Item:
There are no files associated with this item.
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.